An update in the initial management of paediatric status epilepticus
Ben Lawton1,2,3, Tessa Davis4, Henry Goldstein1,2
1Emergency Department, Lady Cilento Children's Hospital, South Brisbane.
Insights
New guidelines for managing status epilepticus emphasize timely seizure termination. Research is evaluating benzodiazepines and exploring alternatives like levetiracetam and lacosamide for second-line treatment.
Area of Science:
- Neurology
- Pharmacology
- Clinical Medicine
Background:
- Status epilepticus management algorithms have evolved.
- Timely seizure termination is a recognized priority.
- Recent research focuses on benzodiazepine choices and second-line treatments.
Purpose of the Study:
- To review current understanding and recent advancements in status epilepticus management.
- To evaluate first-line benzodiazepine options and emerging second-line therapies.
- To discuss the impact of ongoing clinical trials on future treatment algorithms.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of treatment options for status epilepticus.
- Evaluation of efficacy and safety of antiepileptic drugs.
Main Results:
- Benzodiazepines remain the preferred first-line treatment.
- Levetiracetam and lacosamide are being investigated as alternatives to phenytoin.
- Ongoing trials (ESETT, ConSEPT, EcLiPSE) will compare levetiracetam and phenytoin efficacy.
Conclusions:
- Future status epilepticus management algorithms will likely incorporate levetiracetam as a phenytoin alternative.
- Lacosamide may also become a significant treatment option.
- Continued research is crucial for optimizing status epilepticus treatment protocols.
Purpose Of Review:
Over the last 2 years, algorithms for the optimal management of status epilepticus have changed, as the medical community has recognized the need to terminate seizures in status in a timely manner. Recent research has evaluated the different choices of benzodiazepine and has given consideration to second-line treatment options.
Recent Findings:
There has been a move to examine alternatives to phenytoin (such as levetiracetam and lacosamide) as second-line agents. Valproate should be used cautiously in view of the potential side effects. Three ongoing trials [Established Staus Epilepticus Treatment Trial (ESETT), Convulsive Status Epilepticus Paediatric Trial (ConSEPT), and emergency treatment with levetiracetam or phenytoin in status epilepticus in children (EcLiPSE)] are comparing the efficacy of levetiracetam and phenytoin.
Summary:
Benzodiazepines remain the first-line agent of choice, although there is ongoing discussion about the mode of administration and the best drug to choose. The results of ESETT, ConSEPT, and EcLiPSE will affect our future management of status, as we give consideration to levetiracetam as an alternative to phenytoin. Other medications such as lacosamide may emerge in future algorithms too.
More Related Videos
Related Concept Videos
02:33Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
02:33Initiation of Translation
01:47Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...
01:26Marcia's Theory of Identity Status
02:38S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
01:26Tonsillitis II: Management